AR and prostate carcinoma: Unfortunately, despite an initial response these approaches invariably fail due to aberrant AR signalling mediated by receptor mutations and splice variants, AR amplification and ligand-independent AR activation [3] resulting in the development of castrate-resistant prostate cancer (CRPC).